Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A Bayle; F Peyraud; L Belcaid; M Brunet; M Aldea; R Clodion; P Dubos; D Vasseur; C Nicotra; A Geraud; M Sakkal; L Cerbone; F Blanc-Durand; F Mosele; P Martin Romano; M Ngo Camus; I Soubeyran; E Khalifa; M Alame; L Blouin; D Dinart; C Bellera; A Hollebecque; S Ponce; Y Loriot; B Besse; L Lacroix; E Rouleau; F Barlesi; F Andre; A Italiano

doi:10.1016/j.annonc.2022.08.089

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A Bayle, F Peyraud, L Belcaid, M Brunet, M Aldea, R Clodion, P Dubos, D Vasseur, C Nicotra, A Geraud, M Sakkal, L Cerbone, F Blanc-Durand, F Mosele, P Martin Romano, M Ngo Camus, I Soubeyran, E Khalifa, M Alame, L BlouinD Dinart, C Bellera, A Hollebecque, S Ponce, Y Loriot, B Besse, L Lacroix, E Rouleau, F Barlesi, F Andre, A Italiano^*

^*Corresponding author af dette arbejde

Afdeling for Kræftbehandling

26 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Annals of Oncology
Vol/bind	33
Udgave nummer	12
Sider (fra-til)	1328-1331
Antal sider	4
ISSN	0923-7534
DOI	https://doi.org/10.1016/j.annonc.2022.08.089
Status	Udgivet - dec. 2022

Adgang til dokumentet

10.1016/j.annonc.2022.08.089

Andre filer og links

Link to publication in Scopus

Citationsformater

Bayle, A., Peyraud, F., Belcaid, L., Brunet, M., Aldea, M., Clodion, R., Dubos, P., Vasseur, D., Nicotra, C., Geraud, A., Sakkal, M., Cerbone, L., Blanc-Durand, F., Mosele, F., Martin Romano, P., Ngo Camus, M., Soubeyran, I., Khalifa, E., Alame, M., ... Italiano, A. (2022). Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). Annals of Oncology, 33(12), 1328-1331. https://doi.org/10.1016/j.annonc.2022.08.089

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). / Bayle, A; Peyraud, F; Belcaid, L et al.
I: Annals of Oncology, Bind 33, Nr. 12, 12.2022, s. 1328-1331.

Publikation: Bidrag til tidsskrift › Letter › peer review

Bayle, A, Peyraud, F, Belcaid, L, Brunet, M, Aldea, M, Clodion, R, Dubos, P, Vasseur, D, Nicotra, C, Geraud, A, Sakkal, M, Cerbone, L, Blanc-Durand, F, Mosele, F, Martin Romano, P, Ngo Camus, M, Soubeyran, I, Khalifa, E, Alame, M, Blouin, L, Dinart, D, Bellera, C, Hollebecque, A, Ponce, S, Loriot, Y, Besse, B, Lacroix, L, Rouleau, E, Barlesi, F, Andre, F & Italiano, A 2022, 'Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)', Annals of Oncology, bind 33, nr. 12, s. 1328-1331. https://doi.org/10.1016/j.annonc.2022.08.089

Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R et al. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). Annals of Oncology. 2022 dec.;33(12):1328-1331. doi: 10.1016/j.annonc.2022.08.089

@article{33c31ae49a8a41cbac56f3d19fc60111,

title = "Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)",

keywords = "Humans, Precision Medicine, Neoplasms/diagnosis, Liquid Biopsy",

author = "A Bayle and F Peyraud and L Belcaid and M Brunet and M Aldea and R Clodion and P Dubos and D Vasseur and C Nicotra and A Geraud and M Sakkal and L Cerbone and F Blanc-Durand and F Mosele and {Martin Romano}, P and {Ngo Camus}, M and I Soubeyran and E Khalifa and M Alame and L Blouin and D Dinart and C Bellera and A Hollebecque and S Ponce and Y Loriot and B Besse and L Lacroix and E Rouleau and F Barlesi and F Andre and A Italiano",

year = "2022",

month = dec,

doi = "10.1016/j.annonc.2022.08.089",

language = "English",

volume = "33",

pages = "1328--1331",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer

T2 - a study from the French National Center for Precision Medicine (PRISM)

AU - Bayle, A

AU - Peyraud, F

AU - Belcaid, L

AU - Brunet, M

AU - Aldea, M

AU - Clodion, R

AU - Dubos, P

AU - Vasseur, D

AU - Nicotra, C

AU - Geraud, A

AU - Sakkal, M

AU - Cerbone, L

AU - Blanc-Durand, F

AU - Mosele, F

AU - Martin Romano, P

AU - Ngo Camus, M

AU - Soubeyran, I

AU - Khalifa, E

AU - Alame, M

AU - Blouin, L

AU - Dinart, D

AU - Bellera, C

AU - Hollebecque, A

AU - Ponce, S

AU - Loriot, Y

AU - Besse, B

AU - Lacroix, L

AU - Rouleau, E

AU - Barlesi, F

AU - Andre, F

AU - Italiano, A

PY - 2022/12

Y1 - 2022/12

KW - Humans

KW - Precision Medicine

KW - Neoplasms/diagnosis

KW - Liquid Biopsy

UR - http://www.scopus.com/inward/record.url?scp=85143144154&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2022.08.089

DO - 10.1016/j.annonc.2022.08.089

M3 - Letter

C2 - 36122799

SN - 0923-7534

VL - 33

SP - 1328

EP - 1331

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -